Donald Glaser, MD
Ophthalmology · Anderson, SCNPI 1124236062
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Bausch & Lomb Americas Inc. accounts for 64.8% of it on its own, with 25 other manufacturers making up the rest. Among ophthalmology clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 276 payments — averaging $97.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$17K
- Alcon$4K
- Johnson & Johnson Surgical Vision, Inc.$2K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$1K
- NEW World Medical,inc.$1K
- AbbVie$387
- plus $1K from 20 others
What the payments were for
- Consulting fees$1,3325%
- Speaking & faculty fees$11,50043%
- Travel & lodging$1,5566%
- Food & beverage$12,42646%
- Education$180%
- Entertainment$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 42 | $17,391 |
| Alcon | 98 | $3,506 |
| Johnson & Johnson Surgical Vision, Inc. | 11 | $1,827 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 47 | $1,216 |
| NEW World Medical,inc. | 11 | $1,194 |
| AbbVie(2 entities) | 22 | $387 |
| Glaukos Corporation | 3 | $271 |
| Rxsight Inc | 3 | $199 |
| Ocular Therapeutix, Inc. | 3 | $164 |
| Sight Sciences, Inc. | 8 | $113 |
| Novartis | 5 | $89 |
| Omeros Corporation | 4 | $78 |
| Rayner Intraocular Lenses Limited | 3 | $68 |
| Alimera Sciences, Inc. | 2 | $40 |
| Regeneron Healthcare Solutions, Inc. | 2 | $40 |
| Ivantis, Inc | 2 | $40 |
| Quidel Corporation | 1 | $36 |
| Oyster Point Pharma, Inc. | 1 | $28 |
| Astellas Pharma US Inc | 1 | $26 |
| Thea Pharma Inc. | 1 | $24 |
| Harrow Eye, LLC | 1 | $23 |
| Tarsus Pharmaceuticals, Inc. | 1 | $22 |
| Amgen | 1 | $19 |
| Staar Surgical Company | 1 | $18 |
| Dompe US, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IC-8 Apthera IOL$11,171
- enVista MX60 IOL$10,871
- enVista Aspire IOL$2,543
- Tecnis Symfony IOL$1,332
- Ahmed Glaucoma Valve$967
- Kahook Dual Blade$967
- Clearpath$854
- Streamline$854
- Clareon$814
- Via360$499
- ReSTOR$251
- DEXTENZA$128
- AcrySof IQ VIVITY IOL$125
- Tecnis IOL$124
- ENVISTA$124
- STELLARIS$124
- TORIC$124
- AcrySof IQ PanOptix UV IOL$123
- Rhopressa$109
- Rocklatan$109
How this compares
$26,850 in reported general payments places this provider in the 90th percentile of 293 ophthalmology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 33 | $32,540 |
| XiidraLifitegrast | 15 | $20,195 |
| LumiganBimatoprost | 24 | $12,700 |
| CombiganBrimonidine Tartrate/Timolol | 17 | $6,555 |
| Latanoprost | 469 | $5,578 |
| Cyclosporine | 14 | $4,964 |
| Prednisolone Acetate | 123 | $3,461 |
| Ketorolac Tromethamine | 126 | $1,896 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 101 | $1,506 |
| Brimonidine Tartrate | 85 | $1,497 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 12 | $957 |
| MoxifloxacinMoxifloxacin Hcl | 12 | $209 |
| Timolol Maleate | 33 | $173 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $387 | $51,79574 claims |
| Bausch & Lomb Americas Inc.Xiidra | $17,391 | $20,19515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 293 ophthalmology providers in South Carolina.
Other ophthalmology in Anderson
- Kerry SolomonMt Pleasant$1.7M
- William ClarkWest Columbia$768K
- George WaringMt Pleasant$645K
- Karolinne RochaCharleston$552K
- Joseph BishopHilton Head Island$136K
- Erik HappMt Pleasant$124K
- Matthew ClaryColumbia$119K
- Kunal KanitkarLexington$83K
- Carl SloanMyrtle Beach$78K
- David VromanLadson$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.